Accordingly, our molecular investigations (Figures 2(d), 4(b), and 4(c)) unveil a consistent upregulation of cleaved PARP, caspase 3, and caspase 9, which has been observed in cancers treated with AZD1775 or cisplatin [8, 10, 17, 21]. This evidence concerns the gene CASP9 and cancer.